التفاصيل البيبلوغرافية
| العنوان: |
Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. |
| المؤلفون: |
Rijal, Pramila, Elias, Sean C., Machado, Samara Rosendo, Xiao, Julie, Schimanski, Lisa, O'Dowd, Victoria, Baker, Terry, Barry, Emily, Mendelsohn, Simon C., Cherry, Catherine J., Jin, Jing, Labbé, Geneviève M., Donnellan, Francesca R., Rampling, Tommy, Dowall, Stuart, Rayner, Emma, Findlay-Wilson, Stephen, Carroll, Miles, Guo, Jia, Xu, Xiao-Ning |
| المصدر: |
Cell Reports; Apr2019, Vol. 27 Issue 1, p172-172, 1p |
| مستخلص: |
Summary We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP) and boosted with modified vaccinia virus Ankara. Among 82 antibodies isolated from peripheral blood B cells, almost half neutralized GP pseudotyped influenza virus. The antibody response was diverse in gene usage and epitope recognition. Although close to germline in sequence, neutralizing antibodies with binding affinities in the nano- to pico-molar range, similar to "affinity matured" antibodies from convalescent donors, were found. They recognized the mucin-like domain, glycan cap, receptor binding region, and the base of the glycoprotein. A cross-reactive cocktail of four antibodies, targeting the latter three non-overlapping epitopes, given on day 3 of EBOV infection, completely protected guinea pigs. This study highlights the value of experimental vaccine trials as a rich source of therapeutic human monoclonal antibodies. Graphical Abstract Highlights • Therapeutic antibodies for Ebola were isolated from human donors in a vaccine trial • The derived antibodies were close to germline in sequence • Despite temporal immaturity, their binding kinetics matched established antibodies • Vaccine trials can provide a golden opportunity to isolate therapeutic antibodies Most antibodies used for Ebola virus treatment originate from convalescent donors or highly immunized animals. Rijal et al. find that monoclonal antibodies isolated early after vaccination from humans can be powerfully therapeutic, despite the relative immaturity of their sequences. Vaccine trials therefore can provide a valuable source of therapeutic antibodies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cell Reports is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
